12:00 AM
Jan 07, 2013
 |  BC Week In Review  |  Company News  |  Sales & Marketing

NPS sales and marketing update

On Jan. 2, NPS said it set the annual list price for short bowel syndrome (SBS) drug Gattex teduglutide at $295,000. The company, which plans to launch the Orphan drug in February, said it has identified more than 1,000 patients who are eligible for Gattex and expects to have 200-300 patients on the...

Read the full 252 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >